Finance

Lists
CRDF:NASDAQ
Cardiff Oncology Inc
$1.14
+1.79%
(+0.020) 1D
$1.13
-0.88% (-0.0100)
Pre-market
Closed: Oct 5, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRDF...
Open
$1.10
High
$1.15
Low
$1.09
Mkt. cap
88.69M
Avg. vol.
795.03K
Volume
540.00
52-wk high
$3.30
52-wk low
$0.76
EPS
-$0.59
Beta
1.42
Shares outstanding
77.80M
No. of employees
31
Open
$1.10
High
$1.15
Low
$1.09
Mkt. cap
88.69M
Avg. vol.
795.03K
Volume
540.00
52-wk high
$3.30
52-wk low
$0.76
EPS
-$0.59
Beta
1.42
Shares outstanding
77.80M
No. of employees
31
News stories
From web sources and news partners
About Cardiff Oncology Inc
CEOMark Erlander
Employees31
Founded1999
Headquarters-
SectorBiotechnology
Websitecardiffoncology.com
Analyst ratings
Based on 5 analysts giving stock ratings to CRDF in the past 3 months
Buy
Buy
2
Hold
3
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for CRDF in the last 3 months.
Highest
Current $1.14
$9.00 (+689.47%)
Average
$7.50 (+557.89%)
Lowest
$6.00 (+426.32%)
Analyst
Recommendation
Action
Price target
Projected
Date
Albert Lowe
Craig-Hallum
Hold
Maintained
-
-
09/15/2026
Robert Burns
H.C. Wainwright
Buy
Upgraded
$9.00
+689.5%
09/15/2026
Andy Hsieh
William Blair
Hold
Reiterated
-
-
09/14/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$6.00
+426.3%
08/12/2026
Marc Frahm
TD Cowen
Hold
Maintained
-
-
08/12/2026
Christopher Liu
Lucid Capital
Buy
Maintained
$4.00
+250.9%
06/05/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
$12.00
+952.6%
05/22/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
120.00K
243.00K
41.00K
104.00K
Cost of goods sold
8.20M
5.08M
-
-
Cost of revenue
8.20M
5.08M
-
-
Research and development expenses
-
-
6.76M
5.92M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.90M
3.00M
6.13M
3.80M
Operating expense
3.90M
3.00M
12.89M
9.72M
Total operating expenses
12.09M
8.07M
12.89M
9.72M
Operating income
-11.97M
-7.83M
-12.85M
-9.62M
Other non operating income
-
-1.00K
-1.00K
1.00K
EBT including unusual items
-11.26M
-7.22M
-12.34M
-9.23M
EBT excluding unusual items
-11.26M
-7.22M
-12.34M
-9.23M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-11.26M
-7.22M
-12.34M
-9.23M
Net profit margin
-9,381.67%
-2,969.55%
-30,109.76%
-8,876.92%
Earnings per share
-0.17
-0.11
-0.18
-0.14
Interest and investment income
716.00K
612.00K
506.00K
382.00K
Interest expense
-
-
-
-
Net interest expenses
716.00K
612.00K
506.00K
382.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-11.88M
-7.74M
-12.76M
-9.53M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps